+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Research Grants

Children's Leukemia Research Association

CLRA’s Research Grant program provides grants to doctors nationwide. Projects selected for funding are those who are conducting the most promising research into leukemia in the hopes of identifying the causes and improving treatment options that will ultimately lead to a cure. Projects can be exploratory in nature and build on prior work, but funding should not be duplicated from other sources.

We hope that through research, we can find new ways to treat patients and get closer to a cure. And we are.

In the 1940s and 1950s, leukemia was not curable for children. Today, doctors are now able to cure as many as 90% of patients with Acute Lymphocytic Leukemia (ALL). This is in part due to researchers ability to sequence DNA to understand more about how the human body works. Doctors are now able to look at cancer cells versus healthy cells, including genes that may cause cancer.

Applications must be completed on our online portal and are due by June 30th every year.

Grants are awarded for a total of $30,000. Upon approval, the first payment of $15,000 will be made in January. The second payment of $10,000 will be made in July pending receipt of a mid-term report. The third and final payment of $5,000 will be made upon receipt of a final report.

AI Based Application Success Predictor

1. Strong relevance to leukemia and blood cancers

The most competitive proposals directly address:

acute lymphoblastic leukemia (ALL),
acute myeloid leukemia (AML),
pediatric leukemia biology,
blood-cancer therapeutics,
leukemia genomics,
leukemia biomarkers,
treatment resistance,
relapse mechanisms,
hematologic malignancies.

CLRA specifically funds “the most promising leukemia/blood cancer research.”

2. Clear translational and treatment impact

Successful applications usually demonstrate potential to:

improve leukemia treatment,
identify therapeutic targets,
reduce relapse,
improve survival,
reduce toxicity,
improve diagnostic precision.

Applications with realistic pathways toward clinical benefit tend to score highly.

3. Innovative early-stage research

CLRA strongly supports:

exploratory projects,
proof-of-concept studies,
pilot leukemia research,
innovative mechanistic ideas,
early translational concepts.

The organization explicitly notes that projects “can be exploratory in nature” and should support research not duplicated elsewhere.

4. Strong preliminary or feasibility data

Competitive proposals often include:

pilot sequencing findings,
preliminary biomarker data,
feasibility studies,
early therapeutic-response data,
prior leukemia publications.

Even for exploratory projects, strong preliminary evidence substantially improves reviewer confidence.

5. Strong methodological rigor

Successful proposals generally demonstrate:

robust experimental design,
validated leukemia models,
appropriate controls,
realistic timelines,
reproducibility,
sound statistical planning.

Weak methodology is a major reviewer concern across leukemia funding systems.

6. High scientific and clinical significance

Projects are more competitive when they:

address unmet treatment needs,
target resistant leukemia,
improve understanding of leukemia biology,
offer novel therapeutic approaches,
address relapse or toxicity reduction.

High-impact translational potential is heavily valued.

7. Strong investigator and institutional environment

Reviewers favor applicants with:

leukemia research expertise,
hematology-oncology infrastructure,
access to patient samples,
collaborative research environments,
mentorship support for early investigators.

Institutional feasibility strongly influences confidence in project completion.

8. Alignment with unmet or underfunded research areas

CLRA specifically emphasizes funding projects “not duplicated elsewhere.”

Applications may perform better when they:

explore novel concepts,
address neglected leukemia subtypes,
investigate resistant disease,
generate seed data for larger grants.

9. Potential to generate future larger funding

Reviewers favor projects likely to:

lead to NIH/NCI grants,
generate publishable findings,
support clinical trials,
establish longer-term leukemia programs.

Seed-funding potential is an important factor.

10. Clear and focused proposal structure

Strong applications usually present:

a focused hypothesis,
achievable aims,
clear endpoints,
concise translational rationale,
feasible milestones within the grant period.

Overly broad proposals often score poorly.

Specialties

Neurosciences

Pediatrics

Eligibility Requirements

Mid-term reports must be submitted by June 30th. Mid-term reports should include an updated financial report including the original budget as presented vs. actual expenditures to date. A final report is due at the conclusion of the project. Final reports should include a summary of results and a final financial report. Extensions to reporting requirements may be granted depending on circumstances.

Sponsor Details

Sponsor Institute/Organizations: Children's Leukemia Research Association

Sponsor Type: Corporate/Non-Profit

Address: 585 Stewart Avenue Suite 520 Garden City, NY 11530

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity